Objectives: Recently, defects in the protein kinase mTOR (mammalian target of rapamycin) and its associated pathway have been correlated with hemimegalencephaly (HME). mTOR acts as a central regulator of important physiological cellular functions such as growth and proliferation, metabolism, autophagy, death, and survival.
| INTRODUCTION
Hemimegalencephaly (HME) is a rare malformation of cerebral cortical development characterized by enlargement of an entire cerebral hemisphere due to defects in neuronal migration and proliferation defects. 1, 2 The histopathological features of HME resemble focal cortical dysplasia (FCD) type II but, unlike FCD, the lesion extends to the whole hemisphere, resulting in unilateral enlargement. Anatomically, areas of polymicrogyria, pachygyria, and heterotopia may also be present. 3 Clinically, HME patients typically present with refractory epilepsy, which may or may not be associated with focal neurological deficits and delayed neuropsychomotor development of varying severity. They are frequently referred for surgical treatment, with either hemispherectomy or, more often, resection being the procedure of choice. 2, 3 However, satisfactory control of seizures may not be achieved in some HME patients, even after all treatments have been instituted. Thus, genetic and molecular analysis is an important tool to help further understand the molecular and cellular pathogenesis of this disease and the potential viability of therapeutic alternatives. A genetic etiology for HME has long been hypothesized, and recently, somatic variants in genes of the PI3K-Akt-mTOR cell signaling pathway, such as AKT3, PIK3CA, MTOR, and DEPDC5, have been reported. [4] [5] [6] [7] [8] The aim of this study was to identify genetic variants in mTOR signaling pathway genes as well as other parallel pathways. We analyzed DNA from resected brain tissue and paired blood samples of five HME patients who underwent surgical treatment. We identified pathogenic and likely pathogenic variants in several mTOR pathway genes including DEPDC5, PIK3CA, and MTOR. Our results confirm different manifestations of aberrant mTOR signaling, with complex combinations of mosaic variants, suggesting that therapies targeting this pathway may prove useful across a range of cortical development malformations.
| SUBJECTS/MATERIALS AND METHODS

| Patient cohort
Five subjects clinically diagnosed with HME were enrolled in this study. They were all under the age of 7 years at the time of referral and underwent cortical resection procedures to treat refractory epilepsy at the University Hospital of Ribeirão Preto Medical School (HCFMRP-USP). The surgical strategy was decided after an extensive presurgical workup, including magnetic resonance imaging (MRI) scans and video-electroencephalography (EEG) in order to accurately localize the epileptogenic zone. After evaluating all clinical and electroencephalographic data, if a focal, regional, or hemispheric epileptogenic zone was identified, the surgical procedure was proposed.
For each subject, we collected a thorough clinical history and obtained pre-and postoperative brain scans, as well as formalin-fixed and paraffin-embedded affected brain tissue sections stained with neural nuclei (NeuN), glial fibrillary acidic protein (GFAP) and hematoxylin and eosin (H&E), histopathological reports, and Engel surgical outcome scores at one-year follow-up.
Brain samples were obtained via biopsy of brain tissue, as per determined by preoperative scans, and further checked during the surgical procedure with the aid of a neuronavigation stealth system. The biopsied tissue was then fractionated into two parts, one of which was sent for anatomopathological study and another for molecular analysis. Venous blood samples were also collected at the time of surgery.
The protocol for this study received prior approval from the Research Ethics Committee of HCFMRP-USP (Reference Number 6978/2015), and informed consent was obtained from all patients.
| Pathology and Immunohistochemistry
The anterior brain portions were cut into 5-µm-thick coronal sections and mounted on histological slides, which were
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stained with hematoxylin-eosin (H&E), in order to evaluate general cellular architectural patterns, distribution of structures, and cellular density. Glial fibrillary acidic protein (GFAP) assays were performed to assess the distribution and morphological aspects of astrocytes, and NeuN was used to analyze the arrangement of neurons in columns and layers. Spring Bioscience polymer was applied, and slices were incubated overnight at 4°C with the respective primary anti-GFAP antibody 1:2000 (anti-GFAP (DAKO 6F2™)) and anti-NeuN antibody 1:750 (anti-NeuN (CHEMICON A60™)). They were visualized with 3,3′-diaminobenzidine (DAB; Sigma). Next, slides were counter-colored with hematoxylin, washed under running water, dehydrated by serial crescent ethanol solutions and xylol, and covered with Permount™ cover glasses. Photographic documentation was made with an Axioskop2 plus light microscope (Carl Zeiss™) and an AxioCamHrc digital camera (Carl Zeiss), connected to a computer equipped with AxioVision 3.1 software (Carl Zeiss). A 40× objective was used for GFAP and NeuN immunohistochemistry analysis, and a 10× objective was used for H&E stain. Brain tissue and whole blood-derived DNA samples were subjected to exome capture. For this, DNA was extracted using the DNA Purification Kit (Promega) according to the manufacturer's instructions. Libraries were prepared from 250 ng genomic DNA, and exonic regions were captured by using the Nextera Rapid Capture Exome Kit (Illumina). Targeted amplicon sequencing libraries were also carried out for the genomic region of MTOR, PIK3CA, TSC1, TSC2, DEPDC5, and AKT.
Libraries of 125-bp paired-end reads were sequenced on a HiSeq 2500 sequencer (Illumina) with V1 or V4 kits, to achieve a mean coverage of 250× for brain samples and 121× for blood samples. WES and amplicon data were obtained for three patients, whereas two patients had amplicon data only. The variants were filtered, and the variants found by WES were validated using droplet digital PCR (ddPCR).
A mix of ddPCR Supermix (Bio-Rad), mutant and reference probes (0.25 µmol/L each), forward and reverse primers (0.9 µmol/L each), and 30 ng of sample DNA was emulsified into 20 000 droplets using a QX200 Droplet Generator (BioRad). PCR amplification was performed using the following cycles: 10 minutes at 95°C, 40 cycles of 30 seconds at 94°C and 60 seconds at 60°C, 10 minutes at 98°C. Samples were analyzed using QX200 Droplet Reader and QuantaSoft software (Bio-Rad). For all samples, we also screened hotspot variants in PIK3CA and DEPDC5 using ddPCR.
| Bioinformatics analysis
| WES read mapping and filtering
Whole exome sequencing reads from paired brain and blood samples were aligned to the hg19 version of the human reference genome with decoy sequences using bwa-mem with default parameters. Duplicates were marked with Picard's MarkDuplicates (v1.128, http://broad insti tute.github.io/picard), indels were realigned using GATK's IndelRealigner (v3.5), 9 and base quality was recalibrated with GATK, following the GATK 3.5 best practice.
| Amplicon read mapping and filtering
Amplicon sequencing for paired brain and blood samples was performed with random hexamers as unique molecular identifiers (UMIs) to tag individual DNA fragments, and PCR duplicates were removed. UMIs were first removed from amplicon sequencing reads and appended to the read name using umi_tools extract. 10 These reads were then aligned to the hg19 version of the human reference genome with decoy sequences using bwa-mem with default parameters. 9 To remove PCR duplicates, reads were grouped based on their mapped location and UMI, and filtered to yield only one read pair per group using umi_tools dedup. Finally, indels were realigned using GATK's IndelRealigner (v3.5). 
| Variant calling and identification of brain-specific somatic variants
To identify known brain-specific somatic variants, we first compiled a list of variants in mTOR pathway genes, which have been previously associated with cancer or HME cases. 4, 5, 7 We then tabulated the number of read pairs that contained the reference and alternate base at each of these alleles. If a brain sample had at least two alternate reads at one of these known alleles, we treated it as a candidate brainspecific somatic variant.
11
We called novel brain-specific somatic variants using two somatic variant callers: Strelka2 (v2.7.0) 11 and muTect2 (v2). 10 For each individual, we considered the brain sample as the "tumor" and the blood sample as the "normal." We generated high-quality brain-specific somatic calls by taking the intersection of variants identified by both Strelka2 and muTect2. We annotated these calls with protein consequence (eg, synonymous and noncoding) and allele frequencies from the Exome Aggregation Consortium (ExAC) using the SnpEff software (http:/http://snpeff.sourc eforge.net). 12 We further filtered these variants to include only those that resulted in an amino acid change or protein truncation (ie, missense, stop gain, splice site) and that had an ExAC allele frequency <1%. Finally, we annotated the remaining variants in a tab-separated table generated using the SnpEff software and scripts. The variants were annotated with functional consequences using the Ensembl Variant Effect Predictor (VEP). Functional consequences of the variants were evaluated based on the following criteria: (a) Variants occurred in protein-coding regions and canonical splice sites of known FCD-associated; (b) variants were absent from the ExAC database; (c) variants disrupted highly conserved amino acid residues and were predicted to be deleterious by SIFT (score < 0.05) and damaging or probably damaging by PolyPhen (score > 0.85); and (d) variants were predicted to be disease-causing by MutationTaster.
| RESULTS
| Clinical features and genetic analysis
All patients were born at term; age at surgery ranged from 1 to 7 years. They all had frequent seizures refractory to pharmacological therapy and were thus referred for surgical treatment. Preoperative seizure frequency ranged from 1 to 5 a day, including both partial and generalized seizures. Engel outcome measures for these five patients showed clear reductions in seizure frequency at 1 year postsurgery. All cases had clear electrophysiological and semiological features that enabled specific surgical strategies to be reached on an individual basis, similar to the case of patient HME 4143, illustratively described herein. This patient's EEG showed asymmetric disorganization and accentuated basal activity in the left hemisphere along with epileptiform paroxysms of varying morphology and continuous incidence in the frontal and temporal regions of the left cerebral hemisphere (Table 1, Figure 1) .
As per the MRI scans, the right hemisphere was affected in two patients and the left hemisphere in three patients. Scans also showed that all patients had cortical malformations such as broad or flat gyri and shallow sulci (pachygyria or polymicrogyria) and white matter abnormalities (increased volume of white matter, advanced myelination) in the affected hemisphere (Table 1 and Figure 2 ). Most affected individuals show isolated forms of the disease, but HME is occasionally associated with neurocutaneous syndromes, including tuberous sclerosis, hypomelanosis of Ito, and Proteus syndrome. Nevertheless, none of our patients had neurocutaneous syndromes or somatic overgrowth other than the HME.
Histological and immunohistochemistry analyses showed disorganized cortical lamination, presence of balloon cells, Chaslin's gliosis, cytomegalic neurons, dysmorphic neurons, ectopic neurons, polymicrogyria, and intensely marked astrocytes with hypertrophic processes (Table 1 and Figure 2) .
To evaluate the role of somatic mTOR pathway variants in these patients, we performed WES and amplicon sequencing on paired DNA samples from brain and blood. In the three cases selected for WES analysis, a total of 840 variants were found. Protein variants were considered pathogenic if they were frameshift, in-frame deletions, missense, stop gain, splice acceptor, and splice donor variants previously shown to be pathogenic by functional studies, or previously identified in HME or related syndromes. We then focused on the validation of variants found in three mTOR pathway genes that have been previously linked to malformations of cortical development, and on variant types leading to mTOR hyperactivation (gain of function in MTOR and PIK3CA, or loss of function in DEPDC5). The two samples that did not undergo WES were also screened for these variants. We validated four rare and protein-truncating variants in DEPDC5, MTOR, and PIK3CA genes ( Table 1) . In HME 4143, we identified two variants: p.Cys420Arg (c.1258T > C) in PIK3CA, with a variant allele fraction of 22% by ddPCR validation, and p.Arg286Ter (c.856C > T) in DEPDC5 with a 5% variant allele fraction by ddPCR. In HME 4146, we identified p.lle2500Phe (c.7498A > T) in MTOR with a variant allele fraction of 6% by ddPCR. For HME 4149, we found p.Glu542Lys (c.1624G > A) in PIK3CA with an 11% variant allele fraction by ddPCR. In the amplicon analysis for two other cases, we identified the missense variant p.Glu2419Lys (c.7255G > A) in MTOR, with an allele fraction of 9.7% by ddPCR and for HME 6584, and the missense variant p.His1047Arg (c.3140A > G) in PIK3CA, with a variant allele fraction of 13.1% by ddPCR (Table 1, Figure 3) .
The missense variants p.Cys420Arg, p.Glu542Lys, and p.His1047Arg in PIK3CA, and lle2500Phe and p. Glu2419Lys in MTOR genes, are variants classified as presenting a moderate impact according to SnpEff annotation. All the variants in MTOR genes were also predicted as pathogenic and for the missense variants in PIK3CA gene that has been described as benign by the in silico tools. The variant p.Arg286Ter in DEPDC5 gene was the only one classified as presenting high impact according to SnpEff, since it is a nonsense variant. p.Arg286Ter is also predicted as pathogenic by the in silico tools and is characterized as pathogenic by the ClinVar database (https ://www.ncbi.nlm. nih.gov/clinv ar/) ( Table 1 ).
| DISCUSSION
In the present study, we aim to add to the current understanding of which mTOR pathway variants may contribute to HME pathogenesis. Our results suggest that the presence of brain somatic variants, which have been increasingly reported in neurodevelopmental diseases associated with epilepsy, is associated with HME and the presence of seizures. Current understanding of developmental and genetic neuropathology
T A B L E 1 Clinical and genetic findings in HME patients
Clinical characteristics
Patients HME-4143 HME-4146 HME-4149 HME-6584 HME-6593 implicates that FCD type IIb and HME can be included within the spectrum of a single disease. Constitutive activation of mTOR signaling represents a shared pathogenic mechanism in a group of developmental malformations that have histopathological and clinical features in common, such as epilepsy, autism, and other comorbidities. Also, from a neuropathological perspective, the most important distinction between hemimegalencephaly and FCD is their relative extent or the size/volume of the lesion. This difference is related to the onset of the postzygotic somatic mutation with activation of the mTOR pathway. 13, 14 Thus, the characterization of variants in mTOR pathway genes raises the possibility that mTOR inhibitors could have wider therapeutic benefit for patients with focal epilepsy. 7 Of the five studied cases, two presented with MTOR variants and three with missense PIK3CA variants. Those variants have been previously predicted as tentative pathogenic variants by in silico tools, except a mutation in PIK3CA which was described as benign. Even though these somatic variants have a low prevalence, we believe that they may be contributing to the genetic cause of HME in these patients. Dysregulation of the mTOR pathway has been implicated in many pathological conditions, including dysplasias of the central nervous system. Lee and colleagues 5 performed WES on brain tissues and found variants in 6/20 HME patients, in genes of the mTOR pathway such as AKT3, MTOR, and PIK3CA; although they did not find the same variants in paired blood samples, they also suggested that these variants may affect this pathway and might be implicated in or even causing the disease. 5, 6 Recent studies have reported on the prevalence of somatic variants of mTOR pathway genes in patients diagnosed with HME, showing that AKT3 and PIK3CA might be mutated in 8%-10% of the studied cases.
6,7,15 D'Gama et al, using deep sequencing of these mTOR genes, identified an etiology in 27/66 cases (41%). 16 Rivière et al highlight the central role of PI3K/AKT de novo mutations in HME patients, and the power of massive parallel sequencing in the challenging context of phenotypic and genetic heterogeneity combined with postzygotic mosaicism mutations. 17 In general, pathogenic variants in PIK3CA account for 6 to 25% of malformations of cortical development and approximately 31% of HME cases. 4, 6, 7 Another study analyzed 446 tissue samples from 232 patients with intractable epilepsy with various brain pathologies, using deep sequencing of known epilepsy-related genes (up to 28 genes), followed by confirmatory site-specific amplicon sequencing. 18 Pathogenic mutations of mTOR-related genes were discovered in 31.9% (74/232). Baldassari et al enrolled 80 cases in a single-center study and found pathogenic mutations in several mTOR pathway genes, providing a framework for efficient FCD and HME genetic testing, linking neuropathology to recent genetic discoveries, and emphasizing the usefulness of molecular assessment in the children with refractory epilepsy who are thus surgical candidates. 19 More recently, DEPDC5 variants have been detected in patients with focal epilepsy associated with malformations of cortical development. Of the five screened patients, one (HME 4143) had a nonsense variant, which was predicted as pathogenic by in silico tools and which is already characterized as pathogenic in ClinVar. This variant has been previously described as a candidate pathogenic variant associated with epilepsy, and further work is required to elucidate whether patients with epilepsy resulting from DEPDC5 may be at increased risk of epilepsy-related sudden death (SUDEP). 20, 21 According to recent studies, DEPDC5 variants are associated with a spectrum of focal epilepsy phenotypes, ranging from nonlesional familial focal epilepsies to malformation-associated focal epileptic syndromes. 15, 20 Also, variants in this T A B L E 1 (Continued) gene may be associated with a higher rate of refractory epilepsies, as suggested by Baulac and colleagues, 20 who reported that the majority of patients with refractory epilepsy presented with DEPDC5 variants.
DEPDC5 is part of the GATOR1 complex, which inhibits the activity of mTORC1 under amino acid deprivation conditions. It is predicted that loss of function in GATOR1 genes will result in excessive activity of the mTORC1 kinase. Several studies assessed phosphorylation levels of the mTORC1 S6 substrate in brain samples of individuals with GATOR1-related variants. Increased levels of S6 phosphorylation were observed in subjects with DCF IA, DCF IIA, and HME (even with histopathology of DCF IIA), confirming that pathogenic variants in GATOR1 genes are the cause of mTORC1 hyperactivity observed in these cases of CDF and HME. [22] [23] [24] [25] The study by Marsan and colleagues showed that mTORC1 is hyperactivated in DEPDC5 knockout mice and that a single prenatal injection of rapamycin could avoid its overall growth delay, demonstrating that embryonic lethality is caused by hyperactivation of mTORC1. Hughes et al (2017) corroborated these findings and reported blood vascular defects, as well as cortical and lymphatic developmental malformations underlying embryonic lethality in DEPDC5 knockout rats. 26, 27 Our study confirms the presence of DEPDC5 variants in a patient diagnosed with HME and refractory epilepsy, but we believe that the refractory epilepsy should be treated with surgery even in the presence of a clear genetic etiology. The finding that DEPDC5 is associated with cases of HME following hereditary focal epilepsy clarifies the evidence that DEPDC5 acts as an inhibitor of mTORC1, and variants in DEPDC5.
may be responsible for structural changes in the cortex with the presence of dysmorphic cells due to hyperactivation of mTORC1. 20, 24, 26, 28 Finally, we suggest that the somatic variants identified in HME may lead to malformations of cortical development by altering the mTOR signaling cascade. Consistent with this, positively regulated mTOR signaling was found in brain tissue of two of our patients (HME 6584 and HME 4146), in whom we identified somatic missense variants in MTOR. Other studies have also concluded that HME is caused by novel variants in the PIK3CA, AKT3, and MTOR genes, characterizing those variants as one of the molecular causes of HME. 5 These findings reveal the existence of molecular biomarkers belonging to the mTOR pathway. These observations also suggest that HME represents a spectrum of neurodevelopmental disorders resulting from distinct progenitors that are determined at the time the variant occurs during brain development. One variant that occurs early in development may be expected to affect a large number of cells and result in a larger malformation, whereas the same variant occurring later in development could cause a minor malformation. However, identification of such somatic variants will require very high-coverage next-generation sequencing, ideally of affected brain tissue, given that the variant may be present in only a small fraction of cells. 7, 29 Moving forward, it will be critical to perform such ultradeep sequencing, ideally using a targeted list of known and candidate genes, for HME and related disorders.
